Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Sangamo Therapeutics to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
Insider and Institutional Ownership
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Sangamo Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sangamo Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
| Sangamo Therapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Earnings and Valuation
This table compares Sangamo Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Sangamo Therapeutics | $39.55 million | -$122.93 million | -0.19 |
| Sangamo Therapeutics Competitors | $704.12 million | $8.07 million | -17.98 |
Sangamo Therapeutics’ peers have higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Sangamo Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sangamo Therapeutics | -310.81% | -2,662.06% | -132.12% |
| Sangamo Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Volatility and Risk
Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics’ peers have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.
Summary
Sangamo Therapeutics peers beat Sangamo Therapeutics on 8 of the 13 factors compared.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics is a biotechnology company developing genomic medicines for serious diseases. Its research focuses on modifying or regulating genes and using engineered cells to produce potential treatments. The company’s technology platform includes zinc finger proteins, including zinc finger nucleases (ZFNs), which are designed to target specific genetic sequences. Sangamo applies its technologies across gene therapy, cell therapy and gene regulation programs, with research spanning areas such as rare diseases and neurological disorders.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
